Bristol-Myers Squibb has once again flexed its dividend muscles, declaring a $0.60 per share payout on June 17, 2025, continuing its impressive 95-year streak of dividend payments. The new dividend, ...

Bristol-Myers Squibb Company (NYSE:BMY) is the third biopharmaceutical company on the list of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 17, the company ...

In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult ...

Bristol’s autoimmune treatment Sotyktu didn’t miss its cue either. In a Phase 3 trial, over half the patients with psoriatic arthritis reported at least a 20% improvement in symptoms.

BARCELONA -- The oral drug deucravacitinib (Sotyktu) passed what is probably its final test as a treatment for psoriatic arthritis (PsA), demonstrating superiority over placebo for most of its ...

In other recent news, Bristol-Myers Squibb announced that its oral medication Sotyktu demonstrated significant efficacy in treating psoriatic arthritis in a Phase 3 clinical trial. The trial showed ...

The company recently announced that the late-stage study on Sotyktu (deucravacitinib), an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in adults with active psoriatic arthritis met its primary ...

BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy drugs.

Sotyktu was well tolerated through Week 52, demonstrating a safety profile consistent with previous results of Sotyktu in PsA and PsO. Bristol Myers Squibb will work with key investigators to present ...

Bristol Myers Squibb has appointed Wendy Bartie as EVP, corporate affairs. Bartie started in the role this month, BMS said on LinkedIn. She reports to CEO Chris Boerner, a company representative said.

New data from the POETYK PsA-Phase III trial, presented at the 2025 EULAR Congress, demonstrate that Bristol Myers Squibb’s Sotyktu (deucravacitinib) significantly improves joint and skin symptoms in ...